PA8799401A1 - Uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas - Google Patents
Uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomasInfo
- Publication number
- PA8799401A1 PA8799401A1 PA20088799401A PA8799401A PA8799401A1 PA 8799401 A1 PA8799401 A1 PA 8799401A1 PA 20088799401 A PA20088799401 A PA 20088799401A PA 8799401 A PA8799401 A PA 8799401A PA 8799401 A1 PA8799401 A1 PA 8799401A1
- Authority
- PA
- Panama
- Prior art keywords
- hemangioms
- treatment
- manufacture
- medicinal product
- blocking beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE AL USO DE UN BETA BLOQUEANTE PARA LA FABRICACIÓN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LOS HEMANGIOMAS, POR EJEMPLO DE UN LOS HEMANGIOMAS INFANTILES. EL BETA BLOQUEANTE PUEDE SER UN BETA BLOQUEANTE NO SELECTIVO, POR EJEMPLO PROPANOLOL. LA PRESENTE INVENCIÓN PROPORCIONA UNA ALTERNATIVA A LOS COMPUESTOS CONOCIDOS, POR EJ., CORTICOIDES, INTERFERÓN O VINCRISTINA, QUE SE USAN GENERALMENTE PARA EL TRATAMIENTO DE LOS HEMANGIOMAS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07291273A EP2050441A1 (en) | 2007-10-19 | 2007-10-19 | Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
US98950707P | 2007-11-21 | 2007-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8799401A1 true PA8799401A1 (es) | 2009-05-15 |
Family
ID=39156667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20088799401A PA8799401A1 (es) | 2007-10-19 | 2008-10-16 | Uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas |
Country Status (31)
Country | Link |
---|---|
US (2) | US8338489B2 (es) |
EP (3) | EP2050441A1 (es) |
JP (1) | JP5552700B2 (es) |
KR (2) | KR20150110827A (es) |
CN (2) | CN103169971A (es) |
AR (1) | AR068927A1 (es) |
AT (1) | ATE512661T1 (es) |
AU (1) | AU2008313405B2 (es) |
BR (1) | BRPI0816536A2 (es) |
CA (1) | CA2701953C (es) |
CL (1) | CL2008003083A1 (es) |
CO (1) | CO6270209A2 (es) |
CY (1) | CY1112604T1 (es) |
DE (1) | DE08838691T1 (es) |
DK (2) | DK2233135T3 (es) |
ES (2) | ES2390534T3 (es) |
HK (1) | HK1148940A1 (es) |
HR (2) | HRP20110659T1 (es) |
IL (1) | IL205129A (es) |
MA (1) | MA31843B1 (es) |
MX (1) | MX2010004295A (es) |
MY (1) | MY156750A (es) |
NZ (1) | NZ584307A (es) |
PA (1) | PA8799401A1 (es) |
PL (2) | PL2233135T3 (es) |
PT (2) | PT2187878E (es) |
RU (1) | RU2471500C2 (es) |
SI (2) | SI2187878T1 (es) |
TN (1) | TN2010000170A1 (es) |
TW (1) | TWI531365B (es) |
WO (1) | WO2009050567A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8987262B2 (en) | 2007-10-19 | 2015-03-24 | Universite de Bordeaux | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
EP2050441A1 (en) | 2007-10-19 | 2009-04-22 | Université Victor Segalen Bordeaux 2 | Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
US8633181B2 (en) | 2009-04-09 | 2014-01-21 | Rutgers, The State University Of New Jersey | Treatment of cutaneous hemangioma |
EP2246044A1 (en) | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
US20140170112A1 (en) * | 2011-03-12 | 2014-06-19 | Vicus Therapeutics, Llc | Compositions for ameliorating systemic inflammation and methods for making and using them |
CN102579412A (zh) * | 2012-02-16 | 2012-07-18 | 山东省立医院 | 一种治疗婴幼儿血管瘤的外用药物及其制备方法 |
CN103536607A (zh) * | 2012-07-10 | 2014-01-29 | 邵金辉 | 土霉素,普罗帕酮和安乃近的抗肿瘤作用 |
CN103054793B (zh) * | 2013-01-05 | 2015-01-21 | 广州军区广州总医院 | 一种用于治疗婴幼儿血管瘤的盐酸普萘洛尔乳膏及其制备方法 |
WO2014150899A1 (en) * | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Topical ophthalmic formulations for treating migraine |
CN104274390B (zh) * | 2014-09-04 | 2017-06-13 | 郑家伟 | 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用 |
RU2584082C1 (ru) * | 2015-01-21 | 2016-05-20 | Ильдар Наилевич Нурмеев | Способ лечения гемангиом |
CN105434337B (zh) * | 2015-04-03 | 2019-08-16 | 武汉科福新药有限责任公司 | 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途 |
CN105106105A (zh) * | 2015-08-14 | 2015-12-02 | 天津市聚星康华医药科技有限公司 | 噻吗洛尔外用制剂治疗婴幼儿血管瘤的应用及其制备方法 |
US20170360829A1 (en) * | 2016-01-27 | 2017-12-21 | Gillies Mcindoe Research Institute | Treatment of vascular anomalies |
RU2617516C1 (ru) * | 2016-03-24 | 2017-04-25 | Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт неотложной детской хирургии и травматологии Департамента здравоохранения города Москвы | Способ лечения младенческих гемангиом |
CN106474061B (zh) * | 2016-12-08 | 2019-01-22 | 黑龙江童医生儿童生物制药有限公司 | 一种盐酸普萘洛尔口服乳剂及其制备方法 |
CN108261411B (zh) * | 2016-12-30 | 2021-04-30 | 武汉科福新药有限责任公司 | 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法 |
US11730707B2 (en) | 2017-08-07 | 2023-08-22 | Alianza Española De Familias De Von Hippel-Lindau-Vhl | Compounds for treating von Hippel-Lindau disease |
CN108299279B (zh) * | 2018-02-09 | 2021-03-23 | 北京梅尔森医药技术开发有限公司 | 取代芳基胺醇化合物及其制备方法和用途 |
CN110314154A (zh) * | 2018-03-28 | 2019-10-11 | 武汉恒信源药业有限公司 | 左旋普萘洛尔在制备治疗血管病变药物中的应用 |
US20210346319A1 (en) * | 2018-10-04 | 2021-11-11 | Emory University | Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto |
RU2701213C1 (ru) * | 2018-12-27 | 2019-09-25 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Способ лечения инфантильных гемангиом |
US11154518B2 (en) * | 2018-12-28 | 2021-10-26 | Chang Gung Memorial Hospital, Linkou | Methods and apparatus for treating a wound |
WO2020242962A1 (en) * | 2019-05-24 | 2020-12-03 | Pediatric Derm Developement Llc | Treatment of infantile hemangioma |
CN111773226A (zh) * | 2019-06-26 | 2020-10-16 | 首都医科大学附属北京儿童医院 | 噻吗洛尔或其盐在制备预防和/或治疗丛状血管瘤的药物中的用途 |
CA3166161A1 (en) * | 2020-01-29 | 2021-08-05 | Paul Frank Davis | Methods and compositions for the treatment of hemangioma |
TWI776584B (zh) * | 2020-07-10 | 2022-09-01 | 長庚醫療財團法人林口長庚紀念醫院 | β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途 |
EP4223283A1 (en) | 2020-09-30 | 2023-08-09 | Nissan Chemical Corporation | Water-soluble complex containing beta- blocker and lecithin |
CN113274348A (zh) * | 2021-06-11 | 2021-08-20 | 四川大学华西医院 | 用于治疗婴幼儿血管瘤的阿替洛尔凝胶、制备方法及应用 |
PL244294B1 (pl) * | 2022-09-20 | 2024-01-03 | Univ Medyczny W Lodzi | Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL301580A (es) * | 1962-12-11 | |||
US3466325A (en) * | 1965-04-30 | 1969-09-09 | Haessle Ab | 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof |
US3657237A (en) * | 1968-05-22 | 1972-04-18 | Frosst & Co Charles E | Process for making 1 2 5-thiadiazoles in the sinister configuration |
GB1253709A (en) | 1968-05-22 | 1971-11-17 | Frosst & Co Charles E | Thiadiazole derivatives |
US3655663A (en) * | 1969-04-21 | 1972-04-11 | Burton K Wasson | 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles |
SE354851B (es) | 1970-02-18 | 1973-03-26 | Haessle Ab | |
AT334385B (de) * | 1973-12-20 | 1976-01-10 | Chemie Linz Ag | Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen |
FR2330383A1 (fr) * | 1975-11-06 | 1977-06-03 | Synthelabo | Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment |
US5116867A (en) * | 1989-06-30 | 1992-05-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | D-propranolol as a selective adenosine antagonist |
US5182102A (en) * | 1991-07-12 | 1993-01-26 | Alcon Laboratories, Inc. | Anti-glaucoma compositions |
ATE502664T1 (de) * | 1993-07-19 | 2011-04-15 | Angiotech Pharm Inc | Herstellungsmethode eines stents mit anti- angiogener zusammensetzung |
PL329851A1 (en) * | 1996-05-01 | 1999-04-12 | Lilly Co Eli | Treatment of diseases associated with vegf |
US6232299B1 (en) * | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
GB9616672D0 (en) * | 1996-08-08 | 1996-09-25 | Scherer Ltd R P | Pharmaceutical compositions |
WO2002090349A1 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel |
US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
EP1781331A1 (en) * | 2004-08-09 | 2007-05-09 | Université Catholique de Louvain | Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases |
TW200716141A (en) * | 2005-05-05 | 2007-05-01 | Combinatorx Inc | Compositions and methods for treatment for neoplasms |
EP2050441A1 (en) | 2007-10-19 | 2009-04-22 | Université Victor Segalen Bordeaux 2 | Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
US8987262B2 (en) | 2007-10-19 | 2015-03-24 | Universite de Bordeaux | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
-
2007
- 2007-10-19 EP EP07291273A patent/EP2050441A1/en not_active Withdrawn
-
2008
- 2008-10-14 TW TW097139397A patent/TWI531365B/zh active
- 2008-10-16 CA CA2701953A patent/CA2701953C/en active Active
- 2008-10-16 CN CN2012104556417A patent/CN103169971A/zh active Pending
- 2008-10-16 PT PT08838691T patent/PT2187878E/pt unknown
- 2008-10-16 SI SI200830362T patent/SI2187878T1/sl unknown
- 2008-10-16 EP EP09015563.1A patent/EP2233135B8/en active Active
- 2008-10-16 PT PT09015563T patent/PT2233135E/pt unknown
- 2008-10-16 BR BRPI0816536A patent/BRPI0816536A2/pt not_active Application Discontinuation
- 2008-10-16 KR KR1020157025385A patent/KR20150110827A/ko not_active Application Discontinuation
- 2008-10-16 EP EP08838691A patent/EP2187878B1/en active Active
- 2008-10-16 US US12/599,266 patent/US8338489B2/en active Active
- 2008-10-16 AT AT08838691T patent/ATE512661T1/de active
- 2008-10-16 MY MYPI2010001459A patent/MY156750A/en unknown
- 2008-10-16 MX MX2010004295A patent/MX2010004295A/es active IP Right Grant
- 2008-10-16 CN CN2008801118925A patent/CN102006864B/zh active Active
- 2008-10-16 WO PCT/IB2008/002746 patent/WO2009050567A2/en active Application Filing
- 2008-10-16 JP JP2010529467A patent/JP5552700B2/ja active Active
- 2008-10-16 ES ES09015563T patent/ES2390534T3/es active Active
- 2008-10-16 NZ NZ584307A patent/NZ584307A/en unknown
- 2008-10-16 PL PL09015563T patent/PL2233135T3/pl unknown
- 2008-10-16 AU AU2008313405A patent/AU2008313405B2/en active Active
- 2008-10-16 ES ES08838691T patent/ES2368299T3/es active Active
- 2008-10-16 KR KR1020107010904A patent/KR101562627B1/ko active IP Right Grant
- 2008-10-16 DK DK09015563.1T patent/DK2233135T3/da active
- 2008-10-16 PA PA20088799401A patent/PA8799401A1/es unknown
- 2008-10-16 RU RU2010112816/15A patent/RU2471500C2/ru active
- 2008-10-16 DK DK08838691.7T patent/DK2187878T3/da active
- 2008-10-16 PL PL08838691T patent/PL2187878T3/pl unknown
- 2008-10-16 SI SI200830749T patent/SI2233135T1/sl unknown
- 2008-10-16 DE DE08838691T patent/DE08838691T1/de active Pending
- 2008-10-17 AR ARP080104555A patent/AR068927A1/es not_active Application Discontinuation
- 2008-10-17 CL CL2008003083A patent/CL2008003083A1/es unknown
-
2010
- 2010-04-08 CO CO10040510A patent/CO6270209A2/es not_active Application Discontinuation
- 2010-04-15 IL IL205129A patent/IL205129A/en active IP Right Grant
- 2010-04-16 TN TN2010000170A patent/TN2010000170A1/fr unknown
- 2010-05-10 MA MA32829A patent/MA31843B1/fr unknown
- 2010-07-19 HK HK11103063.3A patent/HK1148940A1/xx unknown
-
2011
- 2011-09-07 CY CY20111100858T patent/CY1112604T1/el unknown
- 2011-09-13 HR HR20110659T patent/HRP20110659T1/hr unknown
-
2012
- 2012-09-27 HR HRP20120765AT patent/HRP20120765T1/hr unknown
- 2012-11-16 US US13/678,902 patent/US9173858B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8799401A1 (es) | Uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas | |
CL2018002703A1 (es) | Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291) | |
DOP2013000267A (es) | Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3 | |
ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
CR20110103A (es) | Heteroarilos sustituidos | |
CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
ECSP099620A (es) | Derivados de ciclohexano espirociclico | |
CR20140223A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
ECSP11011054A (es) | Péptidos antivirales terapéuticos | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CR20110579A (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
CL2011002494A1 (es) | Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih). | |
CR10548A (es) | 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen | |
UY35129A (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
ECSP11011307A (es) | Comprimidos para terapia de combinacion | |
CY1117860T1 (el) | Διαβλεννογονια χορηγηση 2-(10-υδροξυδεκυλ)-5,6-διμεθοξυ-3-μεθυλ-2,5-κυκλοεξαδιενο-1,4-διονης (ιδεβενονη) | |
ECSP12011658A (es) | Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia | |
CL2012001031A1 (es) | Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros. | |
CL2017001539A1 (es) | Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos | |
BR112012007888A2 (pt) | "métodos de tratamento usando anticorpos anti-ldl oxidada". |